In a report released on July 14, Albin Sandberg from Kepler Capital maintained a Buy rating on Castellum (CTM – Research Report), with a price target of SEK125.00. The company’s shares closed last Friday at $0.43.
According to TipRanks, Sandberg is ranked #8358 out of 8474 analysts.
Castellum has an analyst consensus of Moderate Buy, with a price target consensus of $6.82, which is a 1,481.27% upside from current levels. In a report released on June 29, EF Hutton also initiated coverage with a Buy rating on the stock with a $1.40 price target.
See Insiders’ Hot Stocks on TipRanks >>
CTM market cap is currently $20.41M and has a P/E ratio of -0.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castellum, Inc. is a biotech company, which engages in the development of water treatment and sanitization technologies. It focuses on acquiring and growing technology companies in the area of information technology. The company offers solutions to food, water and health industries. The company was founded by Jean Machetel Ekobo in September 2010 and is headquartered in Phoenix, AZ.
Read More on CTM:
